A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...

People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label ...

In the ever-evolving landscape of healthcare, groundbreaking innovations are not merely celebrated for their scientific ...

Novo Nordisk is a great pick to buy with the stock near its 52-week low. Vertex Pharmaceuticals is helping patients and ...

Eli Lilly in Kinsale is the prime example of developments the president said the US should not have allowed to happen ...

Proficio Capital Partners LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 30.2% in the fourth ...

Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity ... It said it will also be adding two new doses, as competition ...

Discover last week's top S&P 500 healthcare gainers, major market stories, and groundbreaking pharma deals, including weight-loss drug updates.

We recently published a list of 12 Best Quality Stocks to Invest in Now. In this article, we are going to take a look at ...

Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they ...